This article is in the news archive.
Glaxosmithkline teams up with Cambridge to deliver new medicines
GSK has signed its first agreement with the University of Cambridge, which will dedicate a team of academic experts in both neuroscience and metabolic disorders, to develop a novel centrally-acting agent with therapeutic potential for obesity and addictive disorders.
For more information please click here.
Posted on 30/07/2008
Go to the news index page.